Ranosidenib

N/A

Report date: 2025/11/26 17:11:17
NME

Base Information

Drug NameRanosidenib
Drug Alias NameHMPL-306
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitorsIsocitrate dehydrogenase [NADP], mitochondrial inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmicIsocitrate dehydrogenase [NADP], mitochondrial
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsGlioma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdHutchison Medipharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsGlioma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A